245 related articles for article (PubMed ID: 24113862)
1. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Pintova S; Sidhu H; Friedlander PA; Holcombe RF
Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
[TBL] [Abstract][Full Text] [Related]
2. Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature.
Yaşar HA; Akkus E; Heper A; Akay BN; Urun Y; Utkan G
J Oncol Pharm Pract; 2020 Oct; 26(7):1762-1764. PubMed ID: 32089071
[TBL] [Abstract][Full Text] [Related]
3. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
[No Abstract] [Full Text] [Related]
4. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
5. Case Report of Sweet's Syndrome Associated With Autoimmune Hepatitis.
Cinats AK; Haber RM
J Cutan Med Surg; 2017; 21(1):72-74. PubMed ID: 27534778
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
Bhatia S; Huber BR; Upton MP; Thompson JA
J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
[TBL] [Abstract][Full Text] [Related]
7. Case of vemurafenib-induced Sweet's syndrome.
Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
[TBL] [Abstract][Full Text] [Related]
8. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
9. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
10. [Acute neutrophilic febrile dermatosis (Sweet syndrome) associated with melanoma].
Sánchez Conejo-Mir J; Perez Bernal A; Camacho F
Med Cutan Ibero Lat Am; 1990; 18(3):155-8. PubMed ID: 2263090
[TBL] [Abstract][Full Text] [Related]
11. A case of Sweet's syndrome developed after the treatment of herpes simplex infection in a metastatic breast cancer patient.
Coskun U; Gunel N; Senol E; Ilter N; Dursun A; Tuzun D
J Cutan Pathol; 2002 May; 29(5):301-4. PubMed ID: 12100632
[TBL] [Abstract][Full Text] [Related]
12. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature.
Raza S; Kirkland RS; Patel AA; Shortridge JR; Freter C
Int J Oncol; 2013 May; 42(5):1516-22. PubMed ID: 23546524
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
15. Sweet's syndrome--like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia.
Jagdeo J; Campbell R; Long T; Muglia J; Telang G; Robinson-Bostom L
J Am Acad Dermatol; 2007 Apr; 56(4):690-3. PubMed ID: 17367621
[TBL] [Abstract][Full Text] [Related]
16. Acute febrile neutrophilic dermatosis (Sweet's syndrome).
Anzalone CL; Cohen PR
Curr Opin Hematol; 2013 Jan; 20(1):26-35. PubMed ID: 23207661
[TBL] [Abstract][Full Text] [Related]
17. [Orbital myositis associated with ipilimumab].
Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
Zobniw CM; Saad SA; Kostoff D; Barthel BG
Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
[TBL] [Abstract][Full Text] [Related]
19. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
20. Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease.
Caucanas M; Heylen A; Rolland F; Müller G; Olemans C; Sass U; Vanhooteghem O
Int J Dermatol; 2013 Oct; 52(10):1185-8. PubMed ID: 24073904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
